Men in prostate cancer prevention trial more likely to undergo biopsy
the ONA take:
According to new study published in the journal Cancer Epidemiology, Biomarkers and Prevention, men without prostate cancer taking part in the Prostate Cancer Prevention Trial who participate in other aspects of the trial are most likely to undergo a challenging biopsy.
The randomized, double-blind Prostate Cancer Prevention Trial studied the efficacy of finasteride, a 5-alpha reductase inhibitor, for the prevention of prostate cancer.
Researchers analyzed 13,000 healthy men over a 7-year period to identify which factors were linked with an increased willingness to undergo a biopsy. Researchers identified adherence to finasteride, keeping appointments, undergoing required tests, and good health as factors that increased willingness to undergo the procedure.
Among those who underwent a biopsy, 84% were adherent to finasteride and 98% had the required tests (PSA and digital rectal exam) versus 47% and 75%, respectively, of those who did not undergo a biopsy. They also observed an increased willingness to undergo a biopsy if the study site recruited greater than 200 participants and/or had resources that encouraged continued participation throughout the long-term trial.
Monitoring adherence behaviors can allow researchers to identify those may be less willing to comply with study requirements and create strategies to improve adherence for future studies.
Those who participate in other aspects are most likely to undergo a challenging biopsy.
The Prostate Cancer Prevention Trial was a randomized, double-blind, placebo-controlled trial which tested the efficacy of finasteride, a drug used for prostate cancer prevention.
This study was conducted by SWOG – a cancer research cooperative group that designs and conducts multidisciplinary clinical trials.
Researchers at The University of Texas MD Anderson Cancer Center and the Fred Hutchinson Cancer Research Center used a systematic model to identify factors associated with men adhering to the end-of-study (EOS) biopsy requirement of the trial.
The EOS biopsy, an invasive procedure that examines the cells or tissues of the prostate gland to determine if cancer is evident, is an important part of the study.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions
- Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis
- Intermediate Oncotype DX Scores Prognostic of OS in Early-stage Breast Cancer
- Colorectal Cancer and Dietary Fiber: Source Is More Important Than Amount
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|